{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:53:26Z","timestamp":1770792806425,"version":"3.50.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Despite advances in systemic therapy, outcomes of patients with gastric cancer (GC) peritoneal carcinomatosis (PC) remain poor, in part because of poor penetrance of systemic therapy into peritoneal metastasis due to the plasma-peritoneal barrier and anarchic intra-tumoral circulation. Hence, regional treatment approach with administration of chemotherapy directly into the peritoneal cavity (intraperitoneal, IP) under various conditions, combined with or without cytoreductive surgery (CRS) has remained an area of significant research interest. The purpose of this review is to provide high-level evidence for regional treatment approaches in the management of GCPC with limited peritoneal disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A review of the current literature and ongoing clinical trials for regional IP therapies for GCPC was performed. Studies included in this review comprise of phase III randomized controlled trials, non-randomized phase II studies, high-impact retrospective studies, and active ongoing clinical trials for each available IP modality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The three common IP approaches are heated intraperitoneal chemotherapy (HIPEC), normothermic intraperitoneal chemotherapy (NIPEC) and more recently introduced, pressurized intraperitoneal aerosolized chemotherapy (PIPAC). These IP approaches have been combined with systemic therapy and\/or CRS with varying degrees of promising results, demonstrating evidence of improvements in survival rates and peritoneal disease control. Patient selection, optimization of systemic therapy, and completeness of cytoreduction have emerged as major factors influencing the design of contemporary and ongoing trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IP chemotherapy has a clear role in the management of patients with GCPC, and when combined with CRS in appropriately selected patients has the potential to significantly improve survival. Ongoing and upcoming IP therapy clinical trials hold great promise to shape the treatment paradigm for GCPC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12029-023-00994-5","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T08:02:02Z","timestamp":1706256122000},"page":"534-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4728-084X","authenticated-orcid":false,"given":"Amy Y.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-5006","authenticated-orcid":false,"given":"Shaina","family":"Sedighim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-2947","authenticated-orcid":false,"given":"Fatemeh","family":"Tajik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4689-769X","authenticated-orcid":false,"given":"Aaqil M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-7925","authenticated-orcid":false,"given":"Vinodh K.","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-5189","authenticated-orcid":false,"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-8558","authenticated-orcid":false,"given":"Maheswari","family":"Senthil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"994_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"994_CR2","unstructured":"NCI SEER - Cancer Stat Facts: Stomach Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html."},{"key":"994_CR3","doi-asserted-by":"crossref","unstructured":"Thomassen I, Van Gestel YR, Van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ijc.28373.","DOI":"10.1002\/ijc.28373"},{"key":"994_CR4","doi-asserted-by":"crossref","unstructured":"Rawicz-Pruszy\u0144ski K, Mielko J, Pud\u0142o K, Lisiecki R, Skoczylas T, Murawa D, et al. Yield of staging laparoscopy in gastric cancer is influenced by Laur\u00e9n histologic subtype. J Surg Oncol. 2019;120:1148\u201353. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jso.25711.","DOI":"10.1002\/jso.25711"},{"key":"994_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjsurg.2005.10.015","volume":"191","author":"AI Sarela","year":"2006","unstructured":"Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191:134\u20138.","journal-title":"Am J Surg"},{"key":"994_CR6","doi-asserted-by":"crossref","unstructured":"Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V, et al. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin \u2014 a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15. https:\/\/www.pmc\/articles\/PMC4337241\/.","DOI":"10.1186\/s12885-015-1081-8"},{"key":"994_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/01.sla.0000143245.28656.15","volume":"240","author":"M D\u2019Angelica","year":"2004","unstructured":"D\u2019Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808. https:\/\/doi.org\/10.1097\/01.sla.0000143245.28656.15.","journal-title":"Ann Surg"},{"key":"994_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/bjs.4164","volume":"90","author":"F Roviello","year":"2003","unstructured":"Roviello F, Marrelli D, De Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113\u20139. https:\/\/doi.org\/10.1002\/bjs.4164.","journal-title":"Br J Surg"},{"key":"994_CR9","doi-asserted-by":"crossref","unstructured":"Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219:664\u201375. https:\/\/journals.lww.com\/journalacs\/fulltext\/2014\/10000\/rates_and_patterns_of_recurrence_after_curative.8.aspx.","DOI":"10.1016\/j.jamcollsurg.2014.03.062"},{"key":"994_CR10","doi-asserted-by":"crossref","unstructured":"Ji L, Selleck MJ, Morgan JW, Xu J, Babcock BD, Shavlik D, et al. Gastric cancer peritoneal carcinomatosis risk score. Ann Surg Oncol. 2020;27:240\u20137. https:\/\/link.springer.com\/article\/10.1245\/s10434-019-07624-0.","DOI":"10.1245\/s10434-019-07624-0"},{"key":"994_CR11","doi-asserted-by":"crossref","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies results of the EVOCAPE 1 multicentric prospective study. 2000. https:\/\/onlinelibrary.wiley.com\/terms-and-conditions.","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"994_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3:1237. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0515.","journal-title":"JAMA Oncol"},{"key":"994_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347.","journal-title":"Lancet Oncol"},{"key":"994_CR14","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;398:27. https:\/\/www.pmc\/articles\/PMC8436782\/.","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"994_CR15","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"994_CR16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"994_CR17","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363. https:\/\/link.springer.com\/chapter\/10.1007\/978-1-4613-1247-5_4.","DOI":"10.1007\/978-1-4613-1247-5_4"},{"key":"994_CR18","doi-asserted-by":"crossref","unstructured":"Kastelein AW, Vos LMC, van Baal JOAM, Koning JJ, Hira VVV, Nieuwland R, et al. Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer. Clin Exp Metastasis. 2020;37:293. https:\/\/www.pmc\/articles\/PMC7138772\/.","DOI":"10.1007\/s10585-020-10024-4"},{"key":"994_CR19","doi-asserted-by":"crossref","unstructured":"Valle SJ, Alzahrani NA, Liauw W, Sugarbaker PH, Bhatt A, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol. 2016;7:152. https:\/\/www.pmc\/articles\/PMC4818620\/.","DOI":"10.1007\/s13193-016-0498-0"},{"key":"994_CR20","doi-asserted-by":"crossref","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575. https:\/\/www.pmc\/articles\/PMC3087875\/.","DOI":"10.1245\/s10434-011-1631-5"},{"key":"994_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02867","author":"B Rau","year":"2023","unstructured":"Rau B, Lang H, Koenigsrainer A, Gockel I, Rau H-G, Seeliger H, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.22.02867.","journal-title":"J Clin Oncol"},{"key":"994_CR22","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/bjs.11588","volume":"107","author":"RT van der Kaaij","year":"2020","unstructured":"van der Kaaij RT, Wassenaar ECE, Koemans WJ, Sikorska K, Grootscholten C, Los M, et al. Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results. Br J Surg. 2020;107:1520\u20138. https:\/\/doi.org\/10.1002\/bjs.11588.","journal-title":"Br J Surg"},{"key":"994_CR23","doi-asserted-by":"crossref","unstructured":"Koemans WJ, Van Der Kaaij RT, Boot H, Buffart T, Veenhof AAFA, Hartemink KJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19. https:\/\/www.pmc\/articles\/PMC6501330\/.","DOI":"10.1186\/s12885-019-5640-2"},{"key":"994_CR24","doi-asserted-by":"crossref","unstructured":"Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24:3338\u201344. https:\/\/link.springer.com\/article\/10.1245\/s10434-017-6047-4.","DOI":"10.1245\/s10434-017-6047-4"},{"key":"994_CR25","doi-asserted-by":"crossref","unstructured":"Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28:258\u201364. https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08739-5.","DOI":"10.1245\/s10434-020-08739-5"},{"key":"994_CR26","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340.","journal-title":"J Clin Oncol"},{"key":"994_CR27","doi-asserted-by":"crossref","unstructured":"Rau B, Brandl A, Piso P, Pelz J, Busch P, Demtr\u00f6der C, et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23:11\u201322. https:\/\/link.springer.com\/article\/10.1007\/s10120-019-00978-0.","DOI":"10.1007\/s10120-019-00978-0"},{"key":"994_CR28","doi-asserted-by":"crossref","unstructured":"Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183. https:\/\/www.pmc\/articles\/PMC3995601\/.","DOI":"10.1186\/1471-2407-14-183"},{"key":"994_CR29","unstructured":"D2 resection and HIPEC (hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01882933."},{"key":"994_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intra-peritoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110:275. https:\/\/doi.org\/10.1002\/jso.23633.","journal-title":"J Surg Oncol"},{"key":"994_CR31","unstructured":"Gastrectomy + cytoreductive surgery + HIPEC for gastric cancer with peritoneal dissemination. | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03348150."},{"key":"994_CR32","doi-asserted-by":"crossref","unstructured":"Brown ZJ, Hernandez JM, Ripley RT, Davis JL. Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now. J Gastrointest Oncol. 2017;8:1109\u201313. https:\/\/jgo.amegroups.org\/article\/view\/16185\/html.","DOI":"10.21037\/jgo.2017.09.01"},{"key":"994_CR33","unstructured":"Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer with positive peritoneal cytology | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03092518."},{"key":"994_CR34","doi-asserted-by":"crossref","unstructured":"Green BL, Blumenthaler AN, Gamble LA, McDonald JD, Robinson K, Connolly M, et al.\u00a0Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials. Ann Surg Oncol. 2023;30:1852\u201360. https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12761-0.","DOI":"10.1245\/s10434-022-12761-0"},{"key":"994_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","volume":"235","author":"AK Singla","year":"2002","unstructured":"Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179\u201392.","journal-title":"Int J Pharm"},{"key":"994_CR36","doi-asserted-by":"crossref","unstructured":"Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52:405\u201310. https:\/\/link.springer.com\/article\/10.1007\/s00280-003-0680-2.","DOI":"10.1007\/s00280-003-0680-2"},{"key":"994_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jss.2008.06.049","volume":"155","author":"D Soma","year":"2009","unstructured":"Soma D, Kitayama J, Ishigami H, Kaisaki S, Nagawa H. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res. 2009;155:142\u20136.","journal-title":"J Surg Res"},{"key":"994_CR38","first-page":"4071","volume":"32","author":"M Imano","year":"2012","unstructured":"Imano M, Peng Y, Itoh T, Nishikawa M, Satou T, Yasuda A, et al. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res. 2012;32:4071\u20135.","journal-title":"Anticancer Res"},{"key":"994_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4251\/wjgo.v7.i11.285","volume":"7","author":"H Yamaguchi","year":"2015","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Kazama S, Nozawa H, Kawai K, et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes. World J Gastrointest Oncol. 2015;7:285. https:\/\/doi.org\/10.4251\/wjgo.v7.i11.285.","journal-title":"World J Gastrointest Oncol"},{"key":"994_CR40","doi-asserted-by":"crossref","unstructured":"Emoto S, Sunami E, Yamaguchi H, Ishihara S, Kitayama J, Watanabe T. Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. Surg Today. 2014;44:2209\u201320. https:\/\/link.springer.com\/article\/10.1007\/s00595-014-0848-x.","DOI":"10.1007\/s00595-014-0848-x"},{"key":"994_CR41","unstructured":"Chen Y, Wang X-J, Lin R-B, Chen L, Lin G, Guo Z-Q. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis. Tumori. 2014;100:e180\u20138. https:\/\/journals.sagepub.com\/doi\/10.1700\/1660.18188?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed."},{"key":"994_CR42","doi-asserted-by":"publisher","first-page":"12538","DOI":"10.1038\/srep12538","volume":"5","author":"S Yang","year":"2015","unstructured":"Yang S, Feng R, Pan ZC, Jiang T, Xu Q, Chen Q. A comparison of intravenous plus intraperitoneal chemotherapy with intravenous chemotherapy alone for the treatment of gastric cancer: a meta-analysis. Sci Rep. 2015;5:12538. https:\/\/doi.org\/10.1038\/srep12538.","journal-title":"Sci Rep"},{"key":"994_CR43","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel Plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIXGC trial. J Clin Oncol. 2018;36:1922\u20139.","journal-title":"J Clin Oncol"},{"key":"994_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67\u201370.","journal-title":"Ann Oncol"},{"key":"994_CR45","doi-asserted-by":"crossref","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119:3354\u20138. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/cncr.28204.","DOI":"10.1002\/cncr.28204"},{"key":"994_CR46","doi-asserted-by":"crossref","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20:128\u201334. https:\/\/link.springer.com\/article\/10.1007\/s10120-016-0684-3.","DOI":"10.1007\/s10120-016-0684-3"},{"key":"994_CR47","doi-asserted-by":"crossref","unstructured":"Takahashi N, Kanda M, Yoshikawa T, Takiguchi N, Fujitani K, Miyamoto K, et al. A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial. Gastric Cancer. 2018;21:1014\u201323. https:\/\/link.springer.com\/article\/10.1007\/s10120-018-0817-y.","DOI":"10.1007\/s10120-018-0817-y"},{"key":"994_CR48","unstructured":"Chia DKA, Sundar R, Kim G, Ang JJ, Lum JHY, Nga ME, et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022;29:8597\u2013605. https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11998-z."},{"key":"994_CR49","doi-asserted-by":"crossref","unstructured":"Kobayashi D, Kodera Y, Fukushima R, Morita M, Fushida S, Yamashita N, et al. Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Annals of Surgical Oncology 2023. 2023;1\u20139. https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14240-6.","DOI":"10.1245\/s10434-023-14240-6"},{"key":"994_CR50","doi-asserted-by":"crossref","unstructured":"Shinkai M, Imano M, Chiba Y, Hiraki Y, Kato H, Iwama M, et al. Intraperitoneal and systemic chemotherapy for patients with gastric cancer with peritoneal metastasis: a phase II trial. Anticancer Res. 2018;38:5975\u201381. https:\/\/ar.iiarjournals.org\/content\/38\/10\/5975.","DOI":"10.21873\/anticanres.12945"},{"key":"994_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12885-023-10680-1","volume":"23","author":"M Senthil","year":"2023","unstructured":"Senthil M, Dayyani F. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial. BMC Cancer. 2023;23:209. https:\/\/doi.org\/10.1186\/s12885-023-10680-1.","journal-title":"BMC Cancer"},{"key":"994_CR52","unstructured":"Study of sequential systemic therapy + intraperitoneal paclitaxel in gastric\/GEJ peritoneal carcinomatosis | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04762953."},{"key":"994_CR53","doi-asserted-by":"publisher","first-page":"e1744","DOI":"10.1590\/0102-672020230026e1744","volume":"36","author":"MFKP Ramos","year":"2023","unstructured":"Ramos MFKP, Pereira MA, Charruf AZ, Victor CR, Gregorio JVAM, Alban LBV, et al. Intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis: study protocol of a phase II trial. Arq Bras Cir Dig. 2023;36:e1744. https:\/\/doi.org\/10.1590\/0102-672020230026e1744.","journal-title":"Arq Bras Cir Dig"},{"key":"994_CR54","unstructured":"Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05541146."},{"key":"994_CR55","unstructured":"Intraperitoneal paclitaxel plus systemic mFOLFOX6 | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03618758."},{"key":"994_CR56","doi-asserted-by":"crossref","unstructured":"Kang SH, Min SH, Kim JW, Lee E, Park SW, Lee S, et al. Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2022;29:5084\u201391. https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11582-5.","DOI":"10.1245\/s10434-022-11582-5"},{"key":"994_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21:553. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","journal-title":"Ann Surg Oncol"},{"key":"994_CR58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","volume":"20","author":"G Nadiradze","year":"2016","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20:367. https:\/\/doi.org\/10.1007\/s11605-015-2995-9.","journal-title":"J Gastrointest Surg"},{"key":"994_CR59","doi-asserted-by":"crossref","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368\u201377. http:\/\/www.thelancet.com\/article\/S1470204519303183\/fulltext.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"994_CR60","doi-asserted-by":"publisher","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","volume":"3","author":"C Eveno","year":"2018","unstructured":"Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018;3:20180116. https:\/\/doi.org\/10.1515\/pp-2018-0116.","journal-title":"Pleura Peritoneum"},{"key":"994_CR61","unstructured":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric carcinomatosis. Phase II randomized study | ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT04065139?term=NCT04065139&rank=1."},{"key":"994_CR62","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/pp-2016-0017","volume":"1","author":"V Khomyakov","year":"2016","unstructured":"Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1:159. https:\/\/doi.org\/10.1515\/pp-2016-0017.","journal-title":"Pleura Peritoneum"},{"key":"994_CR63","doi-asserted-by":"publisher","first-page":"175883591984640","DOI":"10.1177\/1758835919846402","volume":"11","author":"F Struller","year":"2019","unstructured":"Struller F, Horvath P, Solass W, Weinreich FJ, Strumberg D, Kokkalis MK, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402. https:\/\/doi.org\/10.1177\/1758835919846402.","journal-title":"Ther Adv Med Oncol"},{"key":"994_CR64","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","volume":"43","author":"M Alyami","year":"2017","unstructured":"Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:2178\u201383.","journal-title":"Eur J Surg Oncol"},{"key":"994_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47:123\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"994_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1515\/pp-2022-0111","volume":"7","author":"F Casella","year":"2022","unstructured":"Casella F, Bencivenga M, Rosati R, Fumagalli UR, Marrelli D, Pacelli F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne. Pleura Peritoneum. 2022;7:135. https:\/\/doi.org\/10.1515\/pp-2022-0111.","journal-title":"Pleura Peritoneum"},{"key":"994_CR67","unstructured":"PIPAC in multimodal therapy for patients with oligometastatic peritoneal gastric cancer | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05303714."},{"key":"994_CR68","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1186\/s12885-023-11549-z","volume":"23","author":"M Luksta","year":"2023","unstructured":"Luksta M, Bausys A, Bickaite K, Rackauskas R, Paskonis M, Luksaite-Lukste R, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study. BMC Cancer. 2023;23:1032. https:\/\/doi.org\/10.1186\/s12885-023-11549-z.","journal-title":"BMC Cancer"},{"key":"994_CR69","unstructured":"PIPAC and FOLFOX for gastric cancer peritoneal cancer | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05644249."},{"key":"994_CR70","unstructured":"Neoadjuvant systemic and peritoneal chemotherapy for advanced gastric cancer | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05318794."},{"key":"994_CR71","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942. https:\/\/doi.org\/10.1038\/s41586-022-04508-4.","journal-title":"Nature"},{"key":"994_CR72","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376:687\u201397.","journal-title":"The Lancet"},{"key":"994_CR73","unstructured":"Robotic cytoreduction and hyperthermic intraperitoneal chemotherapy for treatment of gastric cancer with limited peritoneal metastasis, ROBO-CHIP Study | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05753306."},{"key":"994_CR74","doi-asserted-by":"publisher","first-page":"108","DOI":"10.21037\/jgo.2019.11.05","volume":"11","author":"SP Martin","year":"2020","unstructured":"Martin SP, Drake JA, Hernandez JM, Davis JL. Bidirectional chemotherapy in patients with gastric cancer and peritoneal metastasis. J Gastrointest Oncol. 2020;11:108. https:\/\/doi.org\/10.21037\/jgo.2019.11.05.","journal-title":"J Gastrointest Oncol"},{"key":"994_CR75","unstructured":"Intraperitoneal and intravenous paclitaxel chemotherapy with oral capecitabine for gastric adenocarcinoma with peritoneal carcinomatosis | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04034251."}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00994-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-023-00994-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00994-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T15:17:16Z","timestamp":1718810236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-023-00994-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1007\/s12029-023-00994-5","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"25 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article. Therefore, no ethics approval was necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This is a review article. Therefore, no consent was necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"FD has received research grants (to the institution) from AstraZeneca, Bristol-Myers Squibb, Merck, Genentech\/Roche, Taiho, Exelixis, Trishula, Leap Therapeutics; has received a speaker honorarium from Ipsen, Exelixis, Sirtex, Astellas, and Servier; and has received a consultancy honorarium from Sirtex, Astrazeneca, and Exelixis. The other authors (AYL, SS, FT, AMK, VKR, MS) have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}